Angiotensin II type 1 receptor antisense gene therapy prevents altered renal vascular calcium homeostasis in hypertension.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  HYPERTENSION

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.HYP.33.1.360PMID 9931130
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Attenuation of ANG II actions by adenovirus delivery of AT1 receptor antisense in neurons and SMC.

  1998cited by this paper
• Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy.

  1998cited by this paper
• Ion Channels in Vascular Smooth Muscle: Alterations in Essential Hypertension

  1998cited by this paper
• Tissue renin-angiotensin system

  1997cited by this paper
• Losartan versus gene therapy: chronic control of high blood pressure in spontaneously hypertensive rats.

  1997cited by this paper
• Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1-R mRNA antisense.

  1997cited by this paper
• Angiotensin II responses in AT1A receptor-deficient mice: a role for AT1B receptors in blood pressure regulation.

  1997cited by this paper
• Angiotensin II stimulates MAP kinase kinase kinase activity in vascular smooth muscle cells, Role of Raf.

  1996cited by this paper
• Alterations in rat interlobar artery membrane potential and K+ channels in genetic and nongenetic hypertension.

  1996cited by this paper
• Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense.

  1996cited by this paper
• Losartan reduces cardiac mass and improves coronary flow reserve in the spontaneously hypertensive rat

  1996cited by this paper
• Angiotensin II in cell growth and matrix production.

  1995cited by this paper
• Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system.

  1994cited by this paper
• Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension.

  1994cited by this paper
• Hypertension: Pathophysiology, Diagnosis, and Management

  1994cited by this paper
• Epidemiology of hypertension.

  1994influential reference
• Vascular remodelling in hypertension.

  1993cited by this paper
• Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system.

  1993cited by this paper
• Blood pressure, systolic and diastolic, and cardiovascular risks. US population data.

  1993cited by this paper
• Pathophysiology and clinical aspects of hypertensive hypertrophy.

  1993cited by this paper
• Molecular basis of human hypertension: role of angiotensinogen.

  1992cited by this paper
• Cosegregation of the renin allele of the spontaneously hypertensive rat with an increase in blood pressure.

  1990cited by this paper
• Hurricane Gilbert anaemia.

  1989cited by this paper
• Remission of essential hypertension after renal transplantation.

  1983cited by this paper
• Remission of essential hypertension after renal transplantation.

  1983cited by this paper

• Store-operated Ca 2 (cid:1) entry is exaggerated in fresh preglomerular vascular smooth muscle cells of SHR

  2015cites this paper
• Association of Angiotensin II Type 1 Receptor (A1166C) Gene Polymorphism and Its Increased Expression in Essential Hypertension: A Case-Control Study

  2014cites this paper
• Tannic acid down-regulates the angiotensin type 1 receptor through a MAPK-dependent mechanism.

  2012cites this paper
• Investigation of the role of angiotensin 1-9 in cardiomyocyte hypertrophy

  2010cites this paper
• Effect of angiotensin II receptor 1 antisense oligodoexynucleotides on physiological and pathophysiological growth of cardiomyocytes.

  2004cites this paper
• Large-scale production of retroviral vectors for systemic gene delivery.

  2002cites this paper
• Alterations of ion channels in vascular muscle cells and endothelial cells during hypertension and aging

  2002cites this paper
• Systemic Delivery of aTransgene in Intact Animals by a Retroviral Vector.

  2001cites this paper
• The role of the nervous system in hypertension

  2001cites this paper
• Antisense Approaches and the Modulation of Potassium Channel Function in the Cardiovascular System

  2001cites this paper
• Current Perspectives on the Use of Gene Therapy for Hypertension

  2000cites this paper
• Targeting of the renin‐angiotensin system by antisense gene therapy: a possible strategy for the long‐term control of hypertension

  2000cites this paper
• Evaluation of three polymorphisms in the promoter region of the angiotensin II type I receptor gene

  2000cites this paper
• Angiotensin I-converting enzyme antisense gene therapy causes permanent antihypertensive effects in the SHR.

  2000cites this paper
• Angiotensin I-converting enzyme antisense prevents altered renal vascular reactivity, but not high blood pressure, in spontaneously hypertensive rats.

  2000cites this paper
• Inability to induce hypertension in normotensive rat expressing AT(1) receptor antisense.

  2000cites this paper
• Attenuation of hypertension by systemic delivery of retroviral vector containing type I angiotensin II receptor antisense cDNA.

  2000cites this paper
• Permanent cardiovascular protection from hypertension by the AT(1) receptor antisense gene therapy in hypertensive rat offspring.

  1999cites this paper
• Reversal of hypertension by angiotensin II type 1 receptor antisense gene therapy in the adult SHR.

  1999cites this paper
• Gene therapy in the cardiovascular system: an update.

  1999cites this paper
• The potential use of gene therapy in the control of hypertension.

  1999cites this paper
• Ontogenetic aspects of hypertension development: analysis in the rat.

  1999cites this paper
• Is antisense gene therapy a step in the right direction in the control of hypertension?

  1999cites this paper
• Is antisense gene therapy a step in the right direction in the control of hypertension?

  1999influential citation